{
    "Trade/Device Name(s)": [
        "Galen\u2122 Second Read\u2122"
    ],
    "Submitter Information": "Ibex Medical Analytics Ltd.",
    "510(k) Number": "K241232",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN200080"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QPN"
    ],
    "Summary Letter Date": "May 2, 2024",
    "Summary Letter Received Date": "May 2, 2024",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.3750"
    ],
    "Regulation Name(s)": [
        "Software algorithm device to assist users in digital pathology"
    ],
    "Analyte Class(es)": [
        "anatomic pathology"
    ],
    "Analyte(s)": [
        "Prostate adenocarcinoma (AdC)",
        "Atypical small acinar proliferation (ASAP)"
    ],
    "Specimen Type(s)": [
        "Prostate core needle biopsy (PCNB)",
        "Formalin-fixed paraffin embedded (FFPE) tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Philips Ultra Fast Scanner",
        "Philips IMS",
        "Philips PS27QHDCR display",
        "Barco N.V. NV MDPC-8127 display",
        "Computer system with Windows v10 or Mac OS v11 or higher",
        "Web browser (Google Chrome v120 or later)"
    ],
    "Method(s)/Technology(ies)": [
        "Deep convolutional neural network",
        "Image analysis software",
        "Whole slide imaging"
    ],
    "Methodologies": [
        "Digital pathology",
        "Image analysis",
        "Heatmap visualization"
    ],
    "Submission Type(s)": [
        "Software",
        "Accessory",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Galen\u2122 Second Read\u2122 software device using deep learning to flag prostate core needle biopsy slides suspicious for cancer from digital histopathology images.",
    "Indications for Use Summary": "Software to analyze digitized prostate core needle biopsy slides from H&E-stained FFPE tissue, flagging cases initially diagnosed as benign for pathologist review if suspicious for prostate adenocarcinoma, with outputs intended to support but not replace standard diagnosis.",
    "fda_folder": "Pathology"
}